Understanding Allosteric Modulation And Biased Signalling At Family B GPCRs
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
Family B GPCRs are therapeutic targets for drugs treating osteoporosis, hypercalcaemia, Paget’s disease, type II diabetes and are being actively pursued for other diseases that represent major global health burdens. Despite huge financial input, there are no orally available drugs that act on these receptors. This speaks to a lack of mechanistic understanding of how they work. My research focuses on addressing this question and how to exploit these receptors to design and identify better drugs.
This research will push the boundaries of current knowledge in receptor pharmacology and translate this knowledge into clinical outcomes. Receptors are proteins on the surface of our cells that bind hormones, neurotransmitters and pharmaceuticals. By better understanding the complexities of how these receptors work at the molecular level, the objective is to develop improved treatments and better clinical management for a range of medical conditions.
Control Of TGF-beta Superfamily Signalling In Human Disease
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Members of the transforming growth factor ? (TGF-?) family of proteins play crucial roles in adult tissue homeostasis. In recent years a new paradigm has emerged suggesting that inhibition of TGF-? signalling could be an effective strategy for restoring homeostasis in disease-affected tissues. Dr Harrison’s overall research strategy is based on this concept, and is particularly focussed on developing specific antagonists of individual TGF-? proteins.
The Structure And Composition Of The T-Cell Receptor-CD3 Complex
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
My research will use cutting edge imaging techniques to provide a fundamental advance in our understanding of how foreign viruses and pathogens trigger the immune system. Gaining a greater understanding of these central events will facilitate the design of novel therapies to treat immune associated disorders such as transplant rejection, autoimmune disease and some cancers.